Hormonal
Personalized medicine, utilizing genetic screening and pharmacogenomics, improves diabetes management outcomes by tailoring treatment plans to individual genetic makeup, lifestyle, and health characteristics, thereby optimizing medication choices and reducing adverse reactions.
If you have diabetes, ask your doctor about personalized medicine options. This might include genetic testing to predict your risk or response to specific drugs, and using technologies like Continuous Glucose Monitors (CGM) to get real-time feedback. The goal is to move away from a standard 'one-size-fits-all' approach to a plan tailored to your specific genetics and lifestyle, which can reduce side effects and improve long-term health.
Personalized medicine has emerged as a transformative solution, tailoring treatment plans based on individual genetic makeup, lifestyle factors, and health characteristics. ... The utilization of genetic screening facilitates the timely detection of individuals who may be susceptible to developing diabetes, thereby enabling the implementation of focused preventive interventions and adjustments to their lifestyle. ... genetic insights provide valuable guidance to clinicians when it comes to choosing the most appropriate medications for individual patients. This helps to reduce the likelihood of adverse drug reactions and treatment non-responsiveness
Why this rating
This is a review article summarizing various studies; it does not present new primary clinical trial data but synthesizes existing evidence on genetics and biomarkers.
Source
Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine
Fnu Sugandh et al. · Cureus · 2023
DOI 10.7759/cureus.43697
More from this paper
- Continuous Glucose Monitoring (CGM) and closed-loop 'artificial pancreas' systems significantly enhance glycemic control and reduce hypoglycemia risk by providing real-time data and automated insulin delivery.Moderate
- Personalized glycemic targets, adjusted for age, comorbidities, and hypoglycemia risk, improve patient outcomes by minimizing severe hypoglycemic events and enhancing quality of life, compared to rigid standard targets.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →